
Author's Reply

To the Editor,

We appreciate insightful comments regarding our study demonstrating the predictive value of higher diuretic dosing in the first 72 h of hospitalization on the length of hospital stay (1). We are happy to provide further clarification and data to address their concerns in our statistical approaches.




Figure 1. Distribution of LOS and WRF. The figure shows histograms of LOS (left) and WRF (right)

LOS - length of hospital stay; WRF - worsening renal failure

Table 1. Coefficients of regression models for LOS, WRF, readmission, and mortality

Variable	Coefficient	SE	Incidence rate ratio/OR	P value	95% CI
Length of hospital stay (Poisson regression after variable selection) (n=314)					
Total diuretic dose	0.044	0.004	1.045	<0.001	(0.036, 0.052)
EF	-0.005	0.001	0.995	<0.001	(-0.008, -0.003)
COPD	0.268	0.049	1.308	<0.001	(0.170, 0.364)
Infection	0.236	0.050	1.266	<0.001	(0.138, 0.333)
Noncompliance	-0.293	0.053	0.746	<0.001	(-0.397, -0.191)
BUN	0.004	0.001	1.004	<0.001	(0.002, 0.006)
MAP on admission	-0.006	0.001	0.994	<0.001	(-0.008, -0.003)
Worsening renal function (OLS regression with log transformation after variable selection) (n=314)					
Total diuretic dose	0.024	0.005		<0.001	(0.015, 0.034)
CKD	-0.448	0.047		<0.001	(-0.541, -0.354)
30-day readmission (Logistic regression after variable selection) (n=300)					
HF admission in 1 y	1.122	0.3016	3.070	<0.001	(0.540, 1.727)
CVA	0.932	0.3626	2.540	0.01	(0.207, 1.637)
In-hospital mortality (Firth logistic regression after variable selection) (n=314)					
EF	0.061	0.019	1.062	<0.001	(0.026, 0.102)
BUN	0.036	0.011	1.037	0.001	(0.015, 0.058)
BNP	0.001	0.0003	1.001	<0.001	(0.0005, 0.002)
MAP on admission	-0.062	0.023	0.940	0.004	(-0.113, -0.019)

For WRF, 15 points were added to each value (Δ eGFR +15) prior to log transformation because negative values were observed in cases wherein the renal function was lowest on admission then improved throughout the hospital course.

Total diuretic dose indicates the amount of diuretics in 100 mg oral furosemide equivalent administered in the first 72 h of hospitalization (1 unit is 100 mg oral furosemide equivalent).

Covariates included in the Poisson and OLS regression models are total diuretic dose, age, sex, race (white or non-white), EF, history of diabetes, CKD, COPD, infection on admission, noncompliance, BUN, BNP, MAP, and angiotensin-converting enzyme inhibitor use at home. For 30-day readmission, history of CVA, HF admission in 1 year were also added. For in-hospital mortality, history of CVA, HF admission in 1 year, and aldosterone antagonist use at home was added.

EF - ejection fraction; COPD - chronic obstructive pulmonary disease; BUN - blood urea nitrogen; MAP - mean arterial pressure; CKD - chronic kidney disease; HF - heart failure; CVA - cerebrovascular accident; BNP - brain natriuretic peptide; OLS - ordinary least squares; WRF - worsening renal failure; SE - standard error; OR - odds ratio; CI - confidence interval; LOS - length of hospital stay

First, we agree that sodium and troponin levels are indeed important factors that could predict longer length of hospital stay. For this reason, we did in fact include troponin and sodium levels on admission in all statistical models as discussed in our manuscript. Both troponin and sodium levels were excluded during the stepwise selection processes, and we excluded them from Table 1 to make it more readable. Here we report that the mean sodium level (mmol/L) was 138 ± 4.8 , and the median troponin level (ng/mL) was 0.04 (0.02–0.08).

Second, we acknowledge that excluding certain predictors in the statistical model may be a limitation as mentioned in our manuscript. There is no doubt that both presence of edema on admission and change in weight during hospitalization are important predictors. However, it is well known that weights may be inaccurate or missing for a variety of reasons and that it is difficult to get true comparisons on subjective reports of edema. We would echo the challenges in retrospectively collecting accurate data for acute heart failure for particular data points due to these concerns.

Third, we are aware of the skewed distribution in length of hospital stay and WRF as shown in Figure 1. Use of OLS regression models was however advised during the study design phase since our study had enough cases. Since the concern about this statistical approach was brought to our attention, it is important to confirm whether our conclusions remain unchanged in statistical models that fit the nature of our dependent variables. To address this concern, we performed the following analyses with limited variables based on clinical importance: Poisson regression analysis for length of hospital stay, log transformed regression analysis for WRF, logistic regression analysis for readmission, and fifth logistic regression analysis for in-hospital mortality. For WRF, 15 points were added to each value [Δ estimated glomerular filtration rate (Δ eGFR)+15] prior to log transformation because negative values were observed in the cases where renal function was low on admission and then improved throughout the hospital course. In addition to careful selection of clinically important covariates, we conducted further variable selection based on an exhaustive search rather than stepwise selection. The best models having the lowest Bayesian Information Criterion were selected. We present the results of those best models with variable selection in Table 1 since the statistical significance of all covariates did not change with or without variable selection. The results of models before variable selection are provided separately in Supplemental Material 1.

The statistical relationship between higher diuretic dosing and the outcomes remained unchanged. Higher diuretic dosing

was predictive of longer length of hospital stay and greater reduction in eGFR but not of readmission or in-hospital mortality. The interpretation of its relationship (coefficients) however has changed. When total diuretic dose increases by 100 mg oral furosemide equivalent in the first 72 h, the length of hospital stay in days increases by 1.045 times ($e^{0.044}=1.045$) and the eGFR decreases by 2.3% of Δ eGFR+15. Predictors for longer length of hospital stay remain unchanged from the data in our manuscript. Only total diuretic dose in the first 72 h and history of chronic kidney disease remained significant in predicting WRF. Of note, we did not include change in Hct and dichotomized race into white and non-white in this analysis. Angiotensin-converting enzyme inhibitor use at home was an exception, which was no longer statistically significant in this model. For readmission, we did not observe any significant difference in results. We also agree that more cases are needed to better evaluate predictors for in-hospital mortality given its low incident rate, although we confirmed that fifth logistic regression did not identify significant relationship between higher diuretic dosing and in-hospital mortality.

In conclusion, we acknowledge the study limitations in a variable selection; however, these additional analyses still favor our study findings that higher diuretic dosing in the first 72 h of hospitalization predicts inpatient outcomes including length of hospital stay and WRF.

Hirotaka Kato, **Xiaoshu Li**, **Perry Fisher**, **Dahlia Rizk**
Department of Medicine, Mount Sinai Beth Israel, Icahn School of
Medicine at Mount Sinai; New York-USA
*Center for Health Services Research, University of Kentucky,
Kentucky-USA

Reference

1. Kato H, Fisher P, Rizk D. Higher diuretic dosing within the first 72 h is predictive of longer length of stay in patients with acute heart failure. *Anatol J Cardiol* 2018; 20: 110-6.

Address for Correspondence: Hirotaka Kato, MD,
800 Rose Street, MN 602,
Lexington KY 40536-USA
Phone: 414 955-0350
Fax: 414 955-0094
E-mail: hkato@uky.edu

©Copyright 2018 by Turkish Society of Cardiology - Available online
at www.anatoljcardiol.com

Supplemental Material 1. Results of regression models before variable selection

Table 1. Poisson regression for length of hospital stay (n=314)

Variable	Coefficient	SE	Incidence rate ratio	P-value	Confidence interval
Total diuretic dose	0.044***	0.004	1.045	<0.001	(0.035, 0.052)
Age	-0.001	0.002	0.999	0.623	(-0.004, 0.002)
Sex	0.035	0.046	1.036	0.444	(-0.055, 0.125)
White	0.030	0.046	1.030	0.517	(-0.060, 0.120)
Ejection fraction	-0.005***	0.001	0.995	<0.001	(-0.007, -0.002)
Diabetes mellitus	0.019	0.043	1.019	0.662	(-0.066, 0.104)
Atrial fibrillation	0.054	0.045	1.055	0.233	(-0.034, 0.142)
Chronic kidney disease	0.028	0.046	1.028	0.544	(-0.062, 0.118)
COPD	0.283***	0.051	1.327	<0.001	(0.183, 0.383)
Infection on admission	0.235***	0.051	1.264	<0.001	(0.135, 0.334)
Noncompliance	-0.303***	0.055	0.739	<0.001	(-0.410, -0.196)
Blood urea nitrogen	0.003***	0.001	1.003	0.004	(0.001, 0.006)
BNP	0.00004*	0.00002	1.000	0.056	(0.000001, 0.00008)
MAP on admission	-0.006***	0.001	0.994	<0.001	(-0.008, -0.003)
ACEI at home	0.014	0.042	1.014	0.733	(-0.067, 0.096)
constant	2.233***	0.199	9.328	<0.001	(1.843, 2.624)

***Represents significant at 1% level; **represents significant at 5% level; *represents significant at 10% level.

COPD - chronic obstructive pulmonary disease; BNP - brain natriuretic peptide; MAP - mean arterial pressure; ACEI - angiotensin-converting enzyme inhibitor

Table 2. Log transformed regression for worsening renal function (n=314)

Variable	Coefficient	SE	P-value	Confidence interval
Total diuretic dose	0.023***	0.005	<0.001	(0.013, 0.034)
Age	-0.003	0.002	0.178	(-0.006, 0.001)
Sex	-0.003	0.053	0.952	(-0.107, 0.101)
White	-0.017	0.055	0.755	(-0.125, 0.090)
Ejection fraction	-0.001	0.001	0.333	(-0.004, 0.001)
Diabetes mellitus	-0.072	0.050	0.149	(-0.170, 0.026)
Atrial fibrillation	-0.065	0.052	0.213	(-0.168, 0.038)
Chronic kidney disease	-0.427***	0.054	<0.001	(-0.533, -0.320)
COPD	0.009	0.063	0.888	(-0.116, 0.134)
Infection on admission	0.042	0.063	0.506	(-0.083, 0.167)
Noncompliance	-0.075	0.060	0.217	(-0.194, 0.044)
Blood urea nitrogen	0.0005	0.002	0.757	(-0.003, 0.004)
BNP	-0.00002	0.00003	0.407	(-0.0001, 0.00003)
MAP on admission	0.0006	0.002	0.709	(-0.003, 0.004)
ACEI at home	0.057	0.049	0.241	(-0.039, 0.153)
constant	3.731***	0.225	<0.001	(3.288, 4.173)

***Represents significant at 1% level; **represents significant at 5% level; *represents significant at 10% level.

COPD - chronic obstructive pulmonary disease; BNP - brain natriuretic peptide; MAP - mean arterial pressure; ACEI - angiotensin-converting enzyme inhibitor

Table 3. Firth Logistic regression for in-hospital mortality (n=314)

Variable	Coefficient	SE	Odd ratio	P-value	Confidence interval
Total diuretic dose	-0.111	0.092	0.895	0.229	(-0.291, 0.070)
Age	0.017	0.034	1.017	0.621	(-0.050, 0.084)
Sex	1.056	0.792	2.875	0.182	(-0.496, 2.608)
White	0.168	0.742	1.183	0.821	(-1.286, 1.622)
Ejection fraction	0.059**	0.026	1.061	0.021	(0.009, 0.110)
Diabetes mellitus	-1.640*	0.941	0.194	0.081	(-3.484, 0.203)
Atrial fibrillation	0.610	0.790	1.840	0.440	(-0.938, 2.158)
Chronic kidney disease	-0.135	0.868	0.873	0.876	(-1.837, 1.566)
COPD	0.124	0.839	1.131	0.883	(-1.521, 1.768)
Infection on admission	-0.155	0.779	0.856	0.842	(-1.681, 1.371)
Noncompliance	-2.738	1.665	0.065	0.100	(-6.002, 0.526)
Blood urea nitrogen	0.059***	0.022	1.061	0.006	(0.017, 0.101)
BNP	0.001**	0.0004	1.001	0.001	(0.0005, 0.002)
MAP on admission	-0.027	0.026	0.973	0.298	(-0.078, 0.024)
ACEI at home	-1.692	1.077	0.184	0.116	(-3.802, 0.418)
HF admission in 1 yr	0.634	0.805	1.885	0.431	(-0.943, 2.211)
Cerebrovascular event	-1.240	1.195	0.289	0.299	(-3.581, 1.101)
AA at home	1.750	1.125	5.753	0.120	(-0.455, 3.954)
constant	-7.265	4.452	0.0007	0.103	(-15.992, 1.461)

***Represents significant at 1% level; **represents significant at 5% level; *represents significant at 10% level.

COPD - chronic obstructive pulmonary disease; BNP - brain natriuretic peptide; MAP - mean arterial pressure; ACEI - angiotensin-converting enzyme inhibitor; HF - heart failure; AA - aldosterone antagonist

Table 4. Logistic regression for 30-day readmission (n=300)

Variable	Coefficient	SE	Odd ratio	P-value	Confidence interval
Total diuretic dose	-0.016	0.034	0.984	0.636	(-0.082, 0.050)
Age	-0.008	0.013	0.992	0.532	(-0.034, 0.017)
Sex	-0.168	0.349	0.846	0.631	(-0.852, 0.517)
White	-0.236	0.367	0.790	0.521	(-0.956, 0.484)
Ejection fraction	-0.012	0.010	0.988	0.227	(-0.031, 0.007)
Diabetes mellitus	0.077	0.338	1.080	0.819	(-0.585, 0.739)
Atrial fibrillation	0.443	0.348	1.557	0.204	(-0.240, 1.126)
Chronic kidney disease	0.090	0.356	1.095	0.800	(-0.608, 0.788)
COPD	0.592	0.390	1.808	0.129	(-0.172, 1.356)
Infection	-0.279	0.445	0.756	0.531	(-1.152, 0.593)
Noncompliance	-0.113	0.389	0.893	0.771	(-0.876, 0.650)
Blood urea nitrogen	0.010	0.010	1.010	0.316	(-0.010, 0.030)
BNP	0.0002	0.0002	1.000	0.227	(-0.0001, 0.0005)
MAP on admission	-0.018*	0.011	0.983	0.094	(-0.038, 0.003)
ACEI at home	-0.378	0.325	0.685	0.245	(-1.015, 0.260)
HF admission in 1 yr	0.837**	0.349	2.308	0.016	(0.153, 1.520)
Cerebrovascular event	0.867**	0.401	2.381	0.030	(0.082, 1.653)
constant	0.280	1.475	1.323	0.849	(-2.611, 3.171)

Note: *** represents significant at 1% level; ** represents significant at 5% level; * represents significant at 10% level.

COPD - chronic obstructive pulmonary disease; BNP - brain natriuretic peptide; MAP - mean arterial pressure; ACEI - angiotensin-converting enzyme inhibitor; HF - heart failure